Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 3

WCLC Updates in Immunotherapy for NSCLC

, , ,

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

EP. 1: WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
EP. 2: WCLC Updates on the Emergence of ADCs in NSCLC
Now Viewing
EP. 3: WCLC Updates in Immunotherapy for NSCLC
EP. 4: WCLC Updates in Neoadjuvant Therapy for NSCLC
EP. 5: WCLC Updates in Locally Advanced NSCLC
EP. 6: WCLC Updates in Small Cell Lung Cancer

Data from the following clinical trials are discussed:

  • OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR-Mutant NSCLC
  • PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
  • OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC